Press Release September 15, 2007

Iti_pr_6

Immunomic Therapeutics, Inc. Ph: 240-731-5232 9290 Gaither Road Fax: 240-597-4061 Gaithersburg, MD 20877 info@immunomictherapeutics.com www.immunomix.com FOR IMMEDIATE RELEASE: September 15, 2007 (Gaithersburg, MD) Immunomic Therapeutics Selected to Present at Mid-Atlantic Diamond Ventures Event Gaithersburg, MD, September 15, 2007 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomix.com) announced today that the Company has been selected to present at the Mid-Atlantic Diamond State Venture Conference to be held on September 28, 2007 at the at the Cira Center in Philadelphia as an Alumni Company. ITI made its debut at a MADV event earlier in the year. The Company has been invited back to report on its progress including the recent agreement that will support a clinical trial of the Company’s therapeutic HIV vaccine next year. Quarterly, Mid-Atlantic Diamond Ventures holds venture presentations to showcase high-growth businesses to the investment community. Companies selected to present at the venture panels are first screened through an application and intensive "scrub session" process by MADV's steering committee, which is comprised of executive leaders and successful entrepreneurs with extensive corporate and entrepreneurial experience. Companies presenting in MADV's Venture Forums have proven business models, achieved some revenues, and have well thought-out strategies to rapidly expand their businesses. Mid-Atlantic Diamond Ventures events are open to the public, including the investment and venture capital community, entrepreneurial companies, service providers, and MADV sponsors and affiliates. Additional information about the event can be found on their website at http://sbm.temple.edu/madv. Dr. Bill Hearl, President & CEO of Immunomic Therapeutics said, “I am looking forward to the opportunity to update the investment community on ITI’s progress. The Company learned a great deal about its business model and how to best position ITI after the February event. As a result, we have made excellent progress on our angel round and we are preparing to position the company for additional significant investment. We are very grateful to the MADV for their support and assistance.” About Mid-Atlantic Diamond Ventures Mid-Atlantic Diamond Ventures (MADV) is a science and high technology business cultivator that provides support to early-stage high technology businesses throughout the Mid-Atlantic region. The cultivator encourages and assists entrepreneurs with innovative scientific ideas or commercially viable technology to start and grow their companies into successful, sustainable technology businesses. Formerly known as Diamond State Ventures, MADV is now an affiliate of the Innovation and Entrepreneurship Institute at Temple University's Fox School of Business. About Immunomic Therapeutics Immunomic Therapeutics was founded in 2005 as a joint effort between Capital Genomix, Inc. and Johns Hopkins University to commercialize the LAMP Technology for cancer, infectious disease and other targets. The core technology is based on the research efforts of Dr. J. Thomas August that began in the mid-1990’s studying intracellular molecular trafficking in dendritic cells. LAMP was found to locate within the cell in the same compartment as the Major Histocompatibility Complex – type II (MHC-II). It was shown that an antigenic protein linked to LAMP would also migrate to the MHC-II compartment. This observation had important ramifications to the development of DNA-based vaccines and Dr. August and JHU were awarded a patent in 1997 for the application of LAMP to genetic vaccines. More recent research has led to the filing of additional patents covering improvements and enhancements for DNA – based vaccines. Immunomic Therapeutics, Inc. (“ITI”) is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing a portfolio of clinical applications based on “LAMP” vaccine technology. ITI offers access to LAMP – based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.

Iti_pr_6

This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI’s technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors. ____________________________ CONTACT: Immunomic Therapeutics, Inc. Bill Hearl, Ph.D., President & CEO 240-731-5232 info@immunomictherapeutics.com